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Circular proteins have been identified in plants (cyclotides),
fungi (amatoxins/phallatoxins), bacteria (bacteriocins/pilins)
and animals (defensins), where they are commonly involved in
host defence against pests and pathogens.[1] Their pesticidal
and antimicrobial activity, along with the high stability and bio-
activity provided by a cyclic backbone, makes them valuable
agricultural and pharmaceutical drug lead molecules, and ne-
cessitates the development of efficient methods for circular-
protein production. Biosynthetic pathways usually involve mul-
tistep post-translational modification of propeptides by proc-
essing enzymes.[2] Direct isolation of endogenous circular pro-
tein is feasible in many instances[3] but usually requires large
quantities of source biomaterial
and does not lend itself to the
introduction of amino acid sub-
stitutions. At present, circular
proteins are most commonly ob-
tained through use of chemical
and/or biological syntheses. Es-
tablished strategies for circular
protein synthesis include the as-
sembly of a linear precursor pep-
tide through solid-phase peptide
synthesis (SPPS), typically with
inclusion of an N-terminal cys-
teine and a C-terminal thioester
enabling cyclization through
native chemical ligation (NCL).[4]
Alternatively, recombinant circu-
lar proteins have been obtained
through bacterial expression of
intein fusion proteins, which
afford circular proteins through
expressed-protein ligation or protein trans-splicing,[5] or using
sortase, a bacterial transpeptidase.[6]
A single C-terminal cysteine is capable of initiating an intra-
molecular N!S acyl shift in native peptide sequences.[7] This
gives rise to an S-acyl intermediate that can be intercepted by
an added thiol, causing cleavage of the protein backbone, lib-
erating cysteine and yielding a C-terminal thioester. This reac-
tion can be selective, depending on the nature of the amino
acid preceding cysteine, and occurs at a significantly slower
rate when cysteine is not positioned at the C terminus.[8] Fur-
thermore the presence of cysteine at the N terminus leads to
spontaneous backbone cyclization, through intramolecular
transthioesterification, and S!N rearrangement forming a pep-
tide bond (Scheme 1).[9]
The cysteine-rich nature of many circular peptides facilitates
the design of sequences containing these necessary labile
sites. This strategy lends itself to the chemical synthesis of cir-
cular peptides;[9] however, the genetic encodability of the nec-
essary labile sites should also enable application to recombi-
nant proteins. Bacterial peptide/protein production has several
advantages over chemical synthesis ; providing efficient access
to large polypeptides that are beyond the scope of SPPS, at
relatively low cost, and facilitating the production of combina-
torial peptide libraries, through straightforward DNA engineer-
ing.[10]
Here we demonstrate the applicability of this strategy to
recombinant proteins using the plant cyclotide kalata B1 (KB1).
Cyclotides are perhaps the most comprehensively studied
family of circular proteins to date, with hundreds of members
identified and numerous 3D structures available.[3] They con-
tain 28–37 amino acids, including six conserved cysteine resi-
dues that form three disulfide bonds, giving rise to a rigid,
Scheme 1. Xaa-Cys motifs undergo N!S acyl shift upon heating and the S-acyl intermediate is ultimately inter-
cepted by an N-terminal cysteine, yielding a cyclic thioester which rearranges to form a peptide bond.
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characteristic “cyclic cystine knot” structure, which is extremely
stable.[11] These cysteines aside, the cyclotide family exhibits
high sequence variability, and consequently cyclotides have
emerged as valuable protein engineering scaffolds for the in-
corporation and stabilisation of bioactive peptide sequences.[12]
KB1, from the tropical herb Oldenlandia affinis, was the first cy-
clotide to be identified and is considered to be the prototypic
family member.[13]
Although synthesis of a 30-residue peptide is within the
bounds of SPPS, the often inefficent production of cysteine-
rich peptide thioesters employing 9-fluorenylmethyloxycarbon-
yl (Fmoc) SPPS chemistry means that less desirable tert-butyl-
oxycarbonyl (Boc) SPPS chemistry (which generally requires
a potentially hazardous HF resin cleavage step) is typically em-
ployed.[14] This synthetic limitation enhances the requirement
for alternative recombinant-based strategies for cyclotide pro-
duction.
Bacterial expression of a recombinant kalata B1 linear pre-
cursor peptide was facilitated through fusion with an N-termi-
nal thioredoxin (Trx) tag, yielding approximately 60 mg of puri-
fied protein per litre of cell culture. Conveniently, one of the
six cysteines of wild-type KB1 is preceded by glycine. These se-
quential glycine and cysteine residues were therefore designat-
ed as the respective C- and N-terminal KB1 residues in the ge-
netically encoded sequence, and a seventh cysteine was ap-
pended to the C terminus to provide a labile Gly-Cys site for
N!S acyl shift. The His-tagged Trx-KB1 fusion protein was pu-
rified through immobilized Ni2+-affinity chromatography (Fig-
ure 1A and Figure S1 in the Supporting Information), and the
linear KB1 peptide was liberated initially through factor Xa pro-
tease (Figures S2 and S3), yielding linear KB1 with an N-termi-
nal cysteine. Subsequently more efficient liberation was ach-
ieved by employing tobacco etch virus (TEV) protease (Fig-
ure 1B). The desired KB1 peptide was purified through re-
versed phase-high performance liquid chromatography (RP-
HPLC) in an unoptimised yield of 35%, based on the Trx-fusion
precursor (Figure 1C), and characterized by mass spectrometry
(Figure 1D, left).
Subsequent in vitro cyclization of the purified linear KB1
peptide was achieved through incubation at 45 8C in the pres-
ence of 10% (w/v) sodium 2-mercaptoethane sulfonate
(MESNa). The reaction proceeded for 48 h, after which the
Figure 1. Production of KB1. A) SDS-PAGE analysis of Ni2+-affinity-purified Trx-KB1 fusion protein. M: molecular weight markers. Lane 1: whole-cell lysate,
lane 2: soluble fraction, lane 3: insoluble fraction, lane 4: column flow-through, lane 5: column wash (5 mm imidazole), lane 6: column wash (20 mm imida-
zole), lanes 7–11: eluted fractions (40–500 mm imidazole). B) TEV protease digestion of the fusion protein shows accumulation of Trx (released linear KB1 is
not visible on the gel). C) Preparative HPLC allows straightforward separation of the released KB1 from Trx. D) Analytical HPLC (lower panel) and MS (upper
panels) characterization of purified linear, cyclic (reduced) and folded KB1 samples. E) HPLC coelution experiment: KB1 (upper panel), native KB1 (isolated
from O. affinis, middle panel) and a 1:1 mixture of each peptide (lower panel).
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linear starting material was almost entirely consumed (Fig-
ure S4). The observed drop in molecular mass of approximately
121 Da in the cyclic product was consistent with the excision
of the C-terminal cysteine residue and backbone cyclization
(Figure 1D, middle panel). In order to demonstrate that we
had produced the correct circular framework, oxidative folding
was performed, as previously described,[13] and confirmed by
a further loss of six mass units (Figure 1D, right). We also ob-
served a characteristic increase in HPLC retention time on a
reversed-phase chromatography column following cyclization
and oxidation (Figure 1D lower panel), due to the exposure of
surface hydrophobic residues in the folded structure,[3] thus
indicating the presence of natively folded KB1. Over 1 mg of
purified folded material was obtained from 2 L cell culture. Fur-
thermore, we carried out analytical coelution RP-HPLC of KB1
in the presence of native KB1 (nKB1) and observed elution of
a single peak, representative of a homogeneous sample (Fig-
ure 1E). Nonetheless, we sought further confirmation of KB1
structural integrity through NMR spectroscopy, including 1H
chemical shift assignment (Figures S5 and S6) as previously de-
scribed.[15] Our KB1 chemical shifts align extremely closely with
those of nKB1, including a diagnostic ring current-shifted Hb in
residue P6, at 0.17 ppm (Figure S5), and near-identical devia-
tions of Ha chemical shifts from random coil values, indicative
of the native structure (Figure 2). We also identified slow-ex-
changing backbone amide protons in residues C5, C15, T16,
S18, V21, C22, T23, R24, L27 and V29 (Figures 2 and S7), as pre-
viously observed for nKB1,[15] which definitively confirmed the
native fold and characteristic hydrogen bond network.
This report represents the first synthesis of a ribosomally de-
rived circular miniprotein without the use of sortase or intein
driven cyclization. Each of these existing protocols find wide
use but each has limitations. Cyclization using sortase requires
incorporation of its five-residue recognition sequence into the
circular product, which may not be desirable. Meanwhile, in-
teins have a tendency to spontaneously undergo in vivo splic-
ing and folding, yielding the product in the bacterial cyto-
plasm.[16] This phenomenon has facilitated in vivo activity
screening of protein libraries,[10] however the inefficiency of the
reaction results in low yields of folded protein,[17] and purifica-
tion of linear precursor for in vitro cyclisation and folding is re-
quired to yield comparable quantities of protein to our report-
ed strategy. We therefore believe that following identification
of circular protein sequence(s) with a desired activity, a thiol-
labile Xaa-Cys might provide a valuable and straightforward
strategy for large-scale production, through purification of a
stable bacterially derived precursor for chemically mediated in
vitro cyclization and folding. Furthermore this method should
prove more robust to difficult cases of poor solubility, since
the required N-terminal cysteine may potentially also be liber-
ated chemically.[18] Inteins and sortase, on the other hand, re-
quire maintenance of tertiary structure for activity and are not
compatible with chaotropic agents. We repeated the cycliza-
tion of linear KB1 in 6m guanidinium hydrochloride, and al-
though the reaction proceeded with decreased efficiency; we
were pleased to observe majority conversion to the circular
product after 72 h (Figure S8).
Due to its cysteine-rich sequence, KB1 represented a chal-
lenging molecule for selective C-terminal N!S acyl shift and
cyclization. Aside from the C-terminal Gly-Cys, KB1 contains
three Val-Cys and two Thr-Cys sequences. Previous studies sug-
gested that cysteine residues preceded by b-branched residues
such as valine or threonine are unreactive to intramolecular
N!S acyl shift at 45 8C.[7] Similarly, intein-mediated synthesis of
KB1 has proved most successful when this glycine, rather than
valine or threonine, is positioned adjacent to the active cys-
teine residue of the intein.[19] Consistent with these observa-
tions, we observed selective reactivity at the C terminus.
In conclusion, we report a versatile new strategy for the
semi-synthesis of circular proteins that complements the few
existing methodologies. The appendage of cysteine to the N
and C termini represents a remarkably simple route to mole-
cules for which both in vivo (i.e. , endogenous) and established
in vitro biosynthesis is rather complex.[20] Here the sequence
has been circularly permuted to position cysteine and glycine
at the circularization junction. In cases where cysteine is not
present, or where it is not present in the desired context (i.e. ,
preceded by Cys/His/Gly) then a non-native Xaa-Cys junction
may need to be introduced. However the location of this junc-
tion can be specifically designed to avoid active sites or surfa-
ces, or desulfurization of the non-native cysteine could be per-
formed if necessary.[21] That the circular product appears stable
to the reverse reaction (i.e. , linearization) is an intriguing
aspect of this methodology, and is currently under investiga-
tion in our laboratory.
Figure 2. Characterisation of kalata B1 through NMR spectroscopy. A) A
ribbon representation of the native KB1 backbone structure, including disul-
fide-bonded cysteines (in yellow). B) A graphical depiction of the deviation
in Ha chemical shift from random coil values for each residue in native KB1
(blue) and our semisynthetic KB1 (orange). * denotes residues in which
slow-exchanging amide protons have been identified (Figure S7).
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